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Introduction: Early administration of antibiotics for sepsis, and of fluid boluses and vasoactive agents for septic
shock, is recommended. Evidence for this in children is limited.
Methods: The Alberta Sepsis Network prospectively enrolled eligible children admitted to the Pediatric Intensive
Care Unit (PICU) with sepsis from 04/2012-10/2014. Demographics, severity of illness, and outcomes variables were
prospectively entered into the ASN database after deferred consent. Timing of interventions were determined by
retrospective chart review using a study manual and case-report-form. We aimed to determine the association of
intervention timing and outcome in children with sepsis. Univariate (t-test and Fisher’s Exact) and multiple linear
regression statistics evaluated predictors of outcomes of PICU length of stay (LOS) and ventilation days.
Results: Seventy-nine children, age median 60 (IQR 22–133) months, 40 (51 %) female, 39 (49 %) with severe
underlying co-morbidity, 44 (56 %) with septic shock, and median PRISM-III 10.5 [IQR 6.0-17.0] were enrolled. Most
patients presented in an ED: 36 (46 %) at an outlying hospital ED, and 21 (27 %) at the Children’s Hospital ED. Most
infections were pneumonia with/without empyema (42, 53 %), meningitis (11, 14 %), or bacteremia (10, 13 %). The
time from presentation to acceptable antibiotic administration was a median of 115.0 [IQR 59.0-323.0] minutes; 20
(25 %) of patients received their antibiotics in the first hour from presentation. Independent predictors of PICU LOS
were PRISM-III, and severe underlying co-morbidity, but not time to antibiotics. In the septic shock subgroup, the
volume of fluid boluses given in the first 2 hours was independently associated with longer PICU LOS (effect size
0.22 days; 95 % CI 0.5, 0.38; per ml/kg). Independent predictors of ventilator days were PRISM-III score and severe
underlying co-morbidity. In the septic shock subgroup, volume of fluid boluses in the first 2 hours was independently
associated with more ventilator days (effect size 0.09 days; 95 % CI 0.02, 0.15; per ml/kg).
Conclusion: Higher volume of early fluid boluses in children with sepsis and septic shock was independently
associated with longer PICU LOS and ventilator days. More study on the benefits and harms of fluid bolus therapy in
children are needed.Introduction
Severe sepsis in children is increasing, associated with
significant mortality, and can be followed by significant
neurocognitive sequelae [1–5]. The surviving sepsis
guidelines aim to improve outcomes in children with
severe sepsis, and recommend resuscitation for signs of* Correspondence: ari.joffe@albertahealthservices.ca
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sions, and appropriate antibiotics, each delivered within
the first hour of presentation [6, 7]. Although a ubiqui-
tous intervention, the evidence for dosing of fluid bolus
therapy (FBT) in septic shock is of very low quality [8].
The evidence for FBT in children is predominantly
based on two observational studies finding improved
outcomes with aggressive FBT in children with septic
shock [9, 10]. Other observational studies in children
have concluded that bundles for recognition and early
resuscitation of septic shock that include aggressive FBT
may reduce mortality and hospital length of stay (LOS)article is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
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clear in most of these studies [11, 12, 14, 15], and
others have limitations including having unusually
high mortality [15, 16], an unclear definition of “early
fluid resuscitation” [16], and retrospective patient identifi-
cation [12–14, 16].
There is also evidence that each hour of delayed anti-
biotic therapy in adults with septic shock is associated
with increasing mortality [17, 18]. Although this is the-
oretically compelling, there is only limited evidence for
this early antibiotic administration in children with sep-
sis [19, 20]. Finally, the evidence for timing of vasoactive
infusions is even more limited; in adults, there are data
to suggest that starting at 1–6 h after onset of septic
shock, or by 14 h after onset of septic shock, is associ-
ated with lower mortality [21, 22].
The Alberta Sepsis Network (ASN) prospectively
enrolled a cohort of children with sepsis admitted to the
only two pediatric intensive care units (PICUs) in Alberta,
Canada. In this study we retrospectively reviewed the
charts of children enrolled at the Stollery Children’s
Hospital PICU to determine timing of antibiotic admin-
istration, and in the septic shock subgroup, timing of
fluid boluses and vasoactive infusions. The objective of
this study was to determine whether there is an asso-
ciation between timing of these interventions and out-
comes in children with sepsis. We hypothesized that
early antibiotics, volume, and vasoactive infusions
would be associated with fewer days of ventilation and
shorter LOS in the PICU.
Methods
Ethics
This study was approved by the Health Research Ethics
Board of the University of Alberta (Pro00008797), and
all enrolled patients gave deferred signed informed con-
sent for participation. Deferred consent allowed enrol-
ment as early as possible in PICU, followed by informed
consent to use blood work and continue in the study
within 3 days of inclusion.
The Alberta sepsis network
The ASN prospectively enrolled all eligible children up
to age 17 y who were admitted to the two PICUs in
Alberta with a diagnosis of sepsis, between April 2010
and March 2014. Sepsis was defined as systemic inflam-
matory response syndrome (SIRS) caused by a suspected
or proven bacterial or fungal infection, with antibiotics
prescribed, and an arterial and/or central venous line in
place [23]. The requirement for an arterial and/or cen-
tral venous line was to facilitate study blood work and
justify deferred consent. Patients were excluded if they
were not expected to survive ≥24 h, were refusing intub-
ation or vasoactive infusions (i.e., palliative care), or ifthey had already had severe sepsis for ≥48 h (defined as
sepsis with cardiovascular dysfunction, acute respiratory
distress syndrome, or two other organ dysfunctions).
Demographic, infection, and severity of illness variables
(including pediatric logistic organ dysfunction (PELOD),
and pediatric risk of mortality (PRISM)-III scores) were
recorded prospectively [24, 25]. Site of infection was
defined as that diagnosed by the attending medical team.
Septic shock was defined as having an infusion of an
inotrope or vasopressor (dopamine, dobutamine, epi-
nephrine, norepinephrine, or milrinone) started (i.e., a
new vasoactive agents started, or a dose change of a
vasoactive agent) on the first calendar day of sepsis. This
was a pragmatic definition, meant to identify children
who almost certainly required FBT according to current
guidelines. Severe underlying co-morbidity was defined
as having a cardiac, neurological, or at least two other
organ systems involved in a chronic disease prior to on-
set of sepsis.
Retrospective data collection
The Stollery Children’s Hospital has the only PICU serving
Northern Alberta, much of Northern British Columbia,
Yukon, the North West Territories and Nunavut, and is
the largest referral center for cardiac surgery, extracor-
poreal life support, and solid organ transplantation for
Western Canada. The charts of all enrolled patients in
our PICU were reviewed to determine the following
information: 1) time of presentation with sepsis: the
admission time to the emergency department (ED), or if
onset was on the hospital ward or PICU, the time when
there was both new fever with a temperature >38.2 °C
and a blood culture had been sent. Both fever and blood
culture were required in the hospitalized PICU or ward
patients because those patients can have recurrent fever,
and performing a blood culture was thought to signify
that a new episode of sepsis was suspected; and 2) anti-
biotic administration time: the antibiotic(s) administered
fulfill the predefined criteria for the type of infection. This
time is at the start of the infusion of intravenous antibiotic
(or time when given enterally, for ciprofloxacin, metro-
nidazole, or trimethoprim-sulfamethoxazole). If more than
one antibiotic is required by the predefined criteria, the
time is the start of the second antibiotic. In patients with
septic shock, the following was also recorded: 1) fluid
bolus time: time from presentation with sepsis to the first
fluid bolus of at least 20 ml/kg (the usually suggested
individual FBT volume) of isotonic intravenous fluid,
including crystalloids (normal saline, Ringer’s lactate,
plasmalyte), and/or colloids (5 % albumin, plasma); 2)
volume of fluid boluses in first 2 h after presentation
(to reflect a pragmatic definition of early FBT in re-
suscitating septic shock); 3) volume of fluid boluses
given from presentation until first vasoactive infusion
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from presentation with sepsis to start of the first intraven-
ous vasoactive infusion.
A case report form and study manual were created
for data collection, definitions, and a predefined list
of acceptable antibiotic(s) for each site of infection
(Additional file 1). This list was based on the pub-
lished Bugs & Drugs handbook [26], and expanded to
include antibiotic choices that were not the local first
choice, but that could be expected to be acceptable
(i.e., antibiotics that are broader spectrum than re-
quired for that infection) [20]. The expanded list was pre-
pared by one of the authors (ARJ) who is a pediatric
infectious diseases specialist.
Statistics
Descriptive results are presented as proportions (per-
centages), mean (standard deviation), or median (IQR).
The primary outcome was the association between tim-
ing of antibiotic administration and PICU LOS. In the
septic shock subgroup, the main outcomes of interest
were the association between timing of antibiotic admin-
istration and the amount of early fluid boluses, and
PICU LOS. Predefined potential predictors of outcome
were: 1) demographic variables: age (in months), and
severe underlying co-morbidity; 2) severity of illness
measures: admission day PRISM-III and PELOD scores; 3)
timing variables in the entire cohort: time to appropriate
antibiotic(s); appropriate antibiotic(s) given within 1 h;
and 4) timing variables in the septic shock subgroup: time
to vasoactive infusion; vasoactive infusion within 3 h; time
to volume bolus of 20 ml/kg; volume of boluses given in
first 2 h; volume boluses of ≤20 ml/kg in first 2 h; and
volume of boluses given prior to the start of the first vaso-
active infusion. Predefined outcomes were: 1) ventilator
days; 2) PICU LOS in days; 3) delta-PELOD: the drop in
PELOD from day 1 to 3 of PICU admission, as an in-
dicator of improvement in organ dysfunction(s); and 4)
mortality by 1 y after the index sepsis admission. Univari-
ate comparisons were performed using the t test for inde-
pendent samples and Fisher’s exact test. Multiple linear
regression analysis was used to determine adjusted effect
sizes for predictor variables of continuous outcomes. Mul-
tiple logistic regression was used to determine association
between potential predictors with mortality by 1 y after
the index sepsis admission. Age, PRISM-III score, and
severe underlying co-morbidity were entered into all re-
gression analyses, and we planned to enter time to antibi-
otic(s), volume boluses given in the first 2 h, and volume
boluses given prior to vasoactive infusion into the regres-
sions, unless univariate analysis suggested other timing
variables were statistically significant and should replace
these variables. For all analyses, a two-sided p value ≤0.05
was considered significant.Results
Description of the cohort
Of 83 patients enrolled in the ASN database, 4 were
excluded due to lost charts, with no way to determine
timing of interventions. Of 79 children included, the me-
dian age was 60 (IQR 22–133) months, 40 (51 %) were
female, 39 (49 %) had severe underlying co-morbidity,
and the median PRISM III score on the day of sepsis
was 10.5 (6.0–17.0). Mortalities by 1 y after the sepsis
admission numbered 5/79 (6.3 %); only one of these oc-
curred during the hospitalization, the others at 5, 6, 11,
and 12 months after the admission. Most patients pre-
sented in an ED: 36 (46 %) at an outlying hospital ED,
and 21 (27 %) at the our Children’s Hospital ED. Only 2
(3 %) had developed sepsis while on our Children’s
Hospital wards, and 20 (25 %) while in the PICU. Most
infections were pneumonia with/without empyema (n = 42,
53 %), meningitis (n = 11, 14 %), or bacteremia (n = 10,
13 %); other sites included intra-abdominal (n = 4, 5 %),
urinary tract (n = 3, 4 %), cellulitis (n = 2, 3 %), and other
(n = 7, 9 %). Median time from presentation to acceptable
antibiotic administration was 115.0 (IQR 59.0–323.0)
minutes; 20 patients (25 %) received their antibiotics
during the first hour after presentation (Fig. 1). There
were 44 patients (56 %) with septic shock, of whom 3
(6.8 %) died by 1 y after the sepsis admission.
Univariate analyses
The association between antibiotic administration within
1 h of presentation and demographics and outcomes is
shown in Table 1. Early administration of antibiotics was
associated with higher PRISM-III score, and longer
PICU LOS. Among the patients with septic shock, the
association between volume ≤20 ml/kg given in the first
2 h and demographics and outcomes is shown in Table 1.
Administration of higher-volume boluses was associated
with older age and higher PRISM-III score, with no dif-
ference in outcomes.
The association between the potential predictors
and dichotomous outcomes of ventilator days >7, PICU
LOS >7 days, and delta-PELOD>median are shown in
Table 2. FBT in those ventilated for at least 7 days was
mean 36.7 (SD 34.9 ml/kg) compared to FBT in those
ventilated for <7 days of mean 20.2 (SD 17.6), p = 0.05
(Table 2). The association between potential predictors
and mortality by 1 y after admission are shown in Table 3.
The FBT volume given in the first 2 h was similar accord-
ing to outcomes of number of PICU days, delta PELOD
from day 1 to 3, and mortality by 1 y (Tables 2 and 3).
Multiple regression analyses
Using multiple logistic regression analysis the independ-
ent predictors of ventilator days, PICU LOS, and delta-
PELOD from day 1 to 3 are shown in Table 4, for both
Fig. 1 Time to administration of appropriate antibiotics after presentation with sepsis
Table 1 Univariate associations with early (within 1 h) appropriate antibiotic therapy and with early therapy with bolus volume over
20 ml/kg in children with sepsis and septic shock, respectively
Variable Abx 0–1 h Abx >1 h P value ≤20 ml/kg in 2 h >20 ml/kg in 2 h P value
Number 20 59 26 18
Age 69 (60) 79 (66) 0.56 56 (52) 120 (62) 0.001
PRISM 15 (7) 11 (7) 0.03 11 (7) 17 (8) 0.006
PELOD 15 (8) 17 (10) 0.44 16 (9) 21 (12) 0.090
Severe underlying disease 11/20 (55 %) 28/59 (47 %) 0.61 15/26 (58 %) 9/18 (50 %) 0.76
ΔPELOD 3.4 (8.4) 6.0 (11.6) 0.35 3.2 (12.7) 10.0 (9.9) 0.067
Ventilator days 10.4 (9.2) 7.1 (8.9) 0.17 6.5 (4.8) 9.1 (7.8) 0.18
PICU days 19.5 (21.2) 10.2 (10.1) 0.01 10.7 (7.4) 17.2 (22.4) 0.17
Comparisons were performed using the t test for independent samples, and Fisher’s exact test as appropriate. Values are presented as mean (standard deviation) or
proportion (percent). Abx appropriate antibiotic therapy, PRISM pediatric risk of mortality score, PELOD pediatric logistic organ dysfunction score, PICU pediatric ICU
van Paridon et al. Critical Care  (2015) 19:293 Page 4 of 9
Table 2 Univariate analysis for predictors of prolonged ventilation and PICU length of stay, and for drop in PELOD score between
days 1 to 3 of sepsis





Number 45 19 33 46 40 35
Age, months 82 (62) 62 (66) 0.17 90 (64) 67 (63) 0.12 60 (65) 94 (59) 0.022
PRISM 10.4 (6.1) 14.5 (8.6) 0.02 10.3 (5.5) 13.0 (8.3) 0.11 11.5 (6.6) 12.7 (7.5) 0.45
PELOD 14.4 (8) 20.7 (11) 0.007 14.4 (8.6) 17.8 (10.4) 0.13 - -
Severe underlying
disease
18/45 (40 %) 19/29 (66 %) 0.056 11/33 (33 %) 28/46 (61 %) 0.022 22/40 (55 %) 14/35 (40 %) 0.25
Delta PELOD 6.9 (8.4) 2.7 (14.0) 0.12 8.1 (8.4) 3.4 (11.9) 0.06 - -
Time to Abx 243 (306) 235 (359) 0.92 223 (296) 243 (336) 0.79 234 (329) 239 (325) 0.95
Abx in first hour 10/45 (22 %) 9/29 (31 %) 0.43 5/33 (15 %) 15/46 (33 %) 0.12 13/40 (33 %) 7/35 (20 %) 0.30
Time to inotropes 546 (395) 428 (342) 0.32 654 (368) 428 (359) 0.056 533 (421) 493 (344) 0.74
Inotropes within 3 h 6/24 (25 %) 5/18 (28 %) 0.66 2/15 (13 %) 9/29 (31 %) 0.27 6/20 (30 %) 4/22 (18 %) 0.34
Time to 20 ml/kg
volume
225 (247) 132 (179) 0.22 212 (220) 185 (252) 0.75 233 (306) 152 (167) 0.32
Volume in 2 h 20.2 (17.6) 36.7 (34.9) 0.05 23 (18.9) 29 (30.2) 0.48 23 (23) 33 (30) 0.27
Volume ≤20 ml/kg
in 2 h
16/24 (67 %) 9/18 (50 %) 0.35 10/15 (67 %) 16/29 (55 %) 0.53 14/20 (70 %) 10/22 (45 %) 0.098
Volume to
inotropes
35.2 (32.1) 46.7 (34.4) 0.27 41 (35) 39 (32) 0.88 37 (28) 46 (36) 0.35
Ventilator days - - - - 10.3 (11.2) 5.8 (5.1) 0.036
PICU days - - - - 15.8 (17.8) 9.7 (8.1) 0.071
Comparisons were performed using the t test for independent samples, and Fisher’s exact test as appropriate. Values are given as mean (standard deviation) or
proportion (percent); times are given in minutes. PICU pediatric ICU, PELOD pediatric logistic organ dysfunction score, Abx antibiotic therapy
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Independent predictors of PICU LOS were PRISM-III
score, and severe underlying co-morbidity, but not time
to antibiotics. In the septic shock subgroup, the volume
of fluid boluses given in the first 2 h was independently
associated with longer PICU LOS (effect size 0.22 days;
95 % CI 0.5, 0.38, per ml/kg; p = 0.01). Independent
predictors of ventilator days were PRISM-III score and
severe underlying co-morbidity. In the septic shockTable 3 Univariate associations with mortality by one year after
the index sepsis admission
Variable Alive (n = 74) Dead (n = 5) P value
Time to appropriate
antibiotics, minutes
247 (325) 45 (30) 0.17
Time to inotrope, minutes 495 (350) 652 (711) 0.74
Volume in 2 h, ml/kg 29 (27) 7 (12) 0.18
Volume to inotrope, ml/kg 42 (32) 17 (29) 0.20
Age, months 80 (65) 25 (26) 0.004
PRISM 11.8 (7.4) 12.0 (5.9) 0.96
PELOD day 1 16.5 (9.7) 15.2 (12.0) 0.78
Severe underlying co-morbidity 35/74 (47 %) 4/5 (80 %) 0.20
Data were analyzed using the t test for independent samples and Fisher’s
exact test as appropriate. Values are given as mean (standard deviation) or
proportion (percent). PRISM pediatric risk of mortality score; PELOD pediatric
logistic organ dysfunction scoresubgroup, volume of fluid boluses in the first 2 h was
also independently associated with more ventilator days
(effect size 0.09 days; 95 % CI 0.02, 0.15, per ml/kg;
p = 0.009). The only independent predictor of the delta-
PELOD was age (effect size 0.042; 95 % CI 0.004, 0.080;
p = 0.032), and in the septic shock subgroup there
were no independent predictors. Using multiple logistic
regression, there were no independent predictors for
mortality by 1 y after admission in the entire cohort, or
the septic shock subgroup.
Discussion
We retrospectively reviewed the timing of antibiotics,
fluid, and vasoactive agents in children who were pro-
spectively enrolled in the ASN database from the PICU
for Northern Alberta. The main findings are the follow-
ing. First, early timing of appropriate antibiotics was as-
sociated with longer PICU LOS on univariate analysis;
however, it was not independently associated with PICU
LOS, ventilator days, or change in PELOD score from
day 1 to 3 in all included children (n = 79) or those with
septic shock (n = 44). This is despite fairly wide variabil-
ity in time to administration of appropriate antibiotics in
the patients (median 115.0; IQR 59.0 − 323.0 minutes).
Second, higher volume of fluid boluses in the first 2 h of
presentation with sepsis was independently associated
Table 4 Multiple linear regression analysis of independent predictors of outcomes in children with sepsis, and with septic shock
Variable PICU days Ventilator days
Effect size 95 % CI P value Effect size 95 % CI P value
PRISM 0.64 0.23, 1.04 0.003 0.30 0.01, 0.59 0.04
Age 0.015 - 0.89 −0.02 - 0.22
Severe underlying disease 7.27 1.34, 13.2 0.017 4.1 - 0.05
Time to antibiotics, minutes −0.010 - 0.92 0.002 - 0.45
Model R2 15.2 % 7.4 %
Subgroup: septic shock
PRISM 0.71 0.16, 1.25 0.012 0.24 0.03, 0.45 0.024
Age 0.05 - 0.30 −0.22 - 0.12
Severe underlying disease 0.29 - 0.06 3.82 0.57, 1.07 0.023
Time to antibiotics, minutes -.067 - 0.63 0.049 - 0.72
Volume in 2 h 0.22 0.05, 0.38 0.010 0.09 0.02, 0.15 0.009
Volume prior to inotropes −0.19 - 0.38 −0.13 - 0.54
Model R2 23.4 % 32.1 %
Analyses were performed using stepwise multiple linear regression, except for ventilator days in the entire cohort, where the variables were forced into the
model. For the drop in pediatric logistic organ dysfunction score (PELOD) from day 1 to 3 of sepsis, the only independent predictor in the entire cohort was age
(effect size 0.042; 95 % CI 0.004, 0.080; p = 0.032); for the septic shock subgroup, there were no independent predictors. PRISM pediatric risk of mortality score
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dren with septic shock. Of note, time to starting vaso-
active agents was not associated with outcomes. Third,
severity of illness (PRISM-III score) and severe under-
lying co-morbidity were independently associated with
longer PICU LOS and more ventilator days. Fourth we
did not identify independent predictors of mortality
by 1 y after the index sepsis admission. These results
are contrary to our initial hypotheses, which were
that early appropriate antibiotics, and more volume
bolus resuscitation, would be associated with improved
outcomes.
The evidence for aggressive FBT has been questioned;
two systematic reviews found that FBT may be harmful
in children [27, 28]. These results are largely driven by
the randomized controlled FEAST trial performed in the
developing world in which FBT led to increased mor-
tality from cardiovascular collapse, regardless of pres-
entation syndrome or initial response to fluid therapy
[29–32]. Two single-center retrospective observational
studies suggest improved outcome in 9 and 24 chil-
dren receiving more FBT for septic shock; however,
these studies involved only 34 and 91 children with
septic shock who had survived to PICU admission,
were inotrope-dependent, and had a pulmonary artery
catheter in situ [9, 10]. In the larger study, children
who had signs of shock that resolved quickly were in-
cluded in the appropriate fluid therapy group; the
median fluid volumes given to children who died
(32.9 ml/kg) were higher than those given to survi-
vors (20 ml/kg) [10, 30]. Theoretically, FBT could
cause harm by several mechanisms: rapid reduction insympathetically mediated compensatory mechanisms;
treatment-induced hyperchloremic metabolic acidosis;
ischemia-reperfusion injury; fluid overload; and endothe-
lial glycocalyx degradation [8, 31–33]. The endothelial gly-
cocalyx has important functions in regulating vasomotor
tone, oncotic gradient, endothelial porosity, microvascular
thrombosis, oxidative stress, and endothelial adhesion of
platelets, red blood cells, and white blood cells [34]. It is
surprising that no evidence exists for the effect of fluid
boluses on outcomes more than a few hours after the
bolus [8]. Contrary to the initial study by Rivers et al. [35],
three large well-conducted randomized controlled trials
of early goal-directed therapy (EGDT) in septic shock
in adults suggest that the EGDT group received more
fluid, inotrope, and blood transfusion than the standard
care group, yet had either equivalent or worse outcomes
[36–39]. Our finding that FBT was independently as-
sociated with longer PICU LOS and ventilator days,
without improving the change in PELOD score be-
tween days 1 and 3 of septic shock, is compatible with
these findings.
Alternatives to FBT may include slower infusion of
volume, or earlier use of vasoactive infusions. The evi-
dence for timing of vasoactive agents in children is weak.
In adults, recent observational studies have found an im-
proved survival if vasoactive agents were started in hours
1–6, or by hour 14 after onset of septic shock [21, 22].
The effect may be confounded by the level of blood
pressure that is aimed for, and the evidence for how low
a level of blood pressure is too low is being questioned
[40]. Nevertheless, in our study, we found no association
between timing of vasoactive agents and outcomes in
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finding, however. First, we did not determine the time of
onset of hypotension, and that is likely a better indicator
of when to start vasoactive agents than time from
presentation with sepsis. Second, we had a small
cohort of children with septic shock (n = 44). Third,
because of the small cohort, we did not analyze out-
comes according to individual agents; it is possible
that one agent may be better than another in deter-
mining outcome, although this has not been shown in
adult studies [41, 42].
Early administration of antibiotics has been associated
with better outcome in septic shock and ICU patients
with infection in many adult observational studies
[17, 43–45]. Each hour of delayed antibiotic adminis-
tration from onset of hypotension has been associated
with increased mortality, although a recent study sug-
gested this may only start after 4 h [17, 22]. This sug-
gests a paradigm of septic shock where the bacterial
load must be reduced early and quickly in order to
prevent the sequelae of uncontrolled infection [18].
Recent data in children suggest early antibiotics are
independently associated with improved outcomes in
septic shock, particularly after a cutoff of 3 h
[18, 19]. We did not find this effect in our cohort.
Nevertheless, we do not suggest that antibiotics can
be safely delayed in children with sepsis, due to limita-
tions of our study.
This study has limitations. This is a single-center
cohort of children admitted to PICU with sepsis and an
arterial and/or central venous line who consented to
enrollment in the ASN database in which extra blood
work was performed for research purposes; thus, not all
children with sepsis were included. It is possible that
the inclusion criteria may have missed children who
responded quickly to FBT, and thus, did not require
PICU admission or an arterial/central line. The number of
children included is modest (n = 79), particularly in the
septic shock subgroup (n = 44). The septic shock subgroup
included only children who went on vasoactive infusions,
and may have missed children who had aggressive FBT
alone. The onset of hypotension was not recorded, and
therefore, we cannot determine timing of interventions
from that event. Not all patients had microbiologically
confirmed infection, and thus, it is possible that some of
the patients may have had non-infection causes of severe
systemic inflammatory response syndrome. The mor-
tality in hospital (1/79, 1.3 %) and 1 y after the sepsis
hospitalization (5/79, 6.3 %) was low, suggesting this
may have been a less sick cohort of PICU sepsis patients.
Finally, the timing of interventions was recorded retro-
spectively from chart review. Nevertheless, this is a cohort
of PICU patients with clinically diagnosed sepsis and re-
flects the real-world situation in managing these patients.We pre-specified primary and secondary outcomes, and
the analysis plan. In addition, the PRISM and PELOD
scores of enrolled patients were comparable to published
pediatric trials with higher mortality (Additional file 2:
Table E1), suggesting the cohort comprised patients with
high severity of illness.
Conclusions
Administration of a higher volume of early fluid boluses
in children with sepsis and septic shock was independ-
ently associated with longer PICU LOS and ventilator
days. There was no adverse effect on outcomes with
administration of early appropriate antibiotics and early
vasoactive infusions. This small single-center observa-
tional study cannot prove cause and effect, and is
hypothesis-generating only. Our results are not sufficient
to suggest a change in clinical practice. Nevertheless, we
believe that the results suggest that more study on the
benefits and harms of FBT in children with sepsis are
needed to better inform management.
Key messages
 Early timing of appropriate antibiotics was not
independently associated with PICU LOS, ventilator
days, or change in PELOD score from days 1 to 3 in
all included children (n = 79) or those with septic
shock (n = 44)
 Higher volume of fluid boluses in the first 2 h of
presentation with sepsis was independently
associated with longer PICU LOS and more
ventilator days in children with septic shock
 More study on the benefits and harms of fluid
bolus therapy in children is needed, as there are
multiple theoretical reasons why fluid boluses may
be harmful
Additional files
Additional file 1: The case report form and study manual for the
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